Relief Therapeutics Holding AG (RLFTF)

[Gls3ms]

https://www.google.com/amp/s/nypost.com/article/potential-covid-19-treatments/amp/

https://www.google.com/amp/s/www.click2houston.com/news/local/2020/08/05/houston-methodist-reports-rapid-recovery-of-covid-19-patients-with-new-drug/%3foutputType=amp


https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228

“Results: Median patient follow-up time is 14 days. So far, all treated patients have survived. Improved radiographic appearance of typical “ground glass” COVID-19 features to varying degrees is seen in all patients within 72 hours. Improvement in blood oxygenation is seen in all patients, with complete remission from respiratory failure in 4 of 6 patients. An average 56% reduction in inflammatory markers was seen, together with a median 4 point reduction in the NIAID Ordinal Scale. 2/6 patients were discharged from the hospital and 1 patient was downgraded to the general medicine floor.

Comment: The short term survival of 6/6 patients with respiratory failure in the setting of COVID-19 and major comorbidity is the most dramatic response ever seen with an antiviral agent. Improvement in radiographic appearance, oxygenation requirement, and inflammatory markers is consistent with in vitro evidence of direct anti-viral effect.”

https://www.google.com/amp/s/www.technologynetworks.com/drug-discovery/news/amp/rlf-100-trial-shows-rapid-recovery-from-respiratory-failure-in-critically-ill-patients-with-covid-338232

“Vasoactive Intestinal Polypeptide (VIP) was first discovered by the late Dr. Sami Said in 1970. Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and to be primarily concentrated in the lungs. VIP has been shown in more than 100 peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation. Most importantly, 70% of the VIP in the body is bound to a rare cell in the lung, the Alveolar Type II cell, which is critical for the transmission of oxygen to the body.  VIP has a 20-year history of safe use in humans in multiple human trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.”